Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Opana ER Prescribers (US)

Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant
Dr. Kuldeepak Sharma
Analysis of: Painkiller Widely Abused in South (www.washingtonpost.com)
This article is sad but consistent with overall increase use / abuse of opioids pain killers such as morphine, oxycodone, and hydrocodone. As a pharmacist & pharmaceutical consultant I think these are main reasons for alarming increase of opioids drugs use in America: The population is getting older....
Luc Jasmin, MD, PhD, Attending Neurosurgeon and a Research Scientist
Cedars-Sinai Medical Center
Analysis of: Medtronic Buys Kyphon For $3.9 Billion (www.forbes.com)
Will the recent purchase of Kyphon by Medtronic signals the end of kyphoplasty? No because arcuoplasty does not restore vertebral height. Vertebroplasty, kyphoplasty and arcuoplasty essentially achieve the same goals, which brings up the question, do we need all three techniques? Arcuoplasty is the...
Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant
Dr. Kuldeepak Sharma
Analysis of: PERSONAL DOSE (online.wsj.com)
The FDA has announced changes in the Warfarin label, recommending that a lower initial Warfarin dose should be considered for patients with certain genetic variations. Warfarin (Coumadin) is a commonly prescribed blood thinner with an exceptionally narrow safe-dosage range that varies dramatically from...
John Hsu, MD, Director of Anesthesiology
Presbyterian Intercommunity Hospital Inc
Analysis of: MDs offer new services, for $3,600 yearly fee (www.boston.com)
Is access to healthcare equal for everyone or only for the wealthy.
Analysis of: Organon's Sugammadex Demonstrated A 9-12 Times Faster Recovery In Phase III Pivotal Trial Compared To Neostigmine (www.medicalnewstoday.com)
1) sugammedex will improve patient safety in terms of post-operative respiratory depression 2) sugammedex will allow anesthesiologist to provide profound muscle relaxation to ensure ideal surgical conditions, with little consequence in terms of overdosing or prolonged post-operative muscle blockade...
Analysis of: Electronic Prescription Drug Act of 2007 (www.thomas.loc.gov)
Legible prescriptions are important because misread handwriting can lead to drug erors and possible fatal outcomes. In pain management,  illegible prescriptions could also possible allow  patients to alter doses/numbers and place both physicians and themselves at jeopardy, as well...
Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant
Dr. Kuldeepak Sharma
Analysis of: Johnson & Johnson Plans to Improve Overall Cost Structure, While Continuing to Invest in Opportunities for Sustained Profitable Growth (www.pipelinereview.com)
Recently Johnson & Johnson announced the cutbacks to improve overall cost structure. Being a Pharmaceutical consultant, I follows industry trend. I think J&J is following the trend since Pfizer, AstraZeneca and Bristol-Meyers Squibb also announced that they would be trimming back staff this...
Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant
Dr. Kuldeepak Sharma
Analysis of: Genta and Emisphere Technologies File IND with FDA for Oral Drug to Treat Bone Disease (www.pipelinereview.com)
As a pharmaceutical consultant, I think this IND will be novel groundbreaking treatment option for the treatment of bone diseases because it is one of first oral tablet formulation that enables oral absorption of gallium nitrate injection for treatment of cancer-related hypocalcaemia. Also this is unique...
Jason Campagna, MD,PhD, Director of Clinical Quality and Analytics
Jason Campagna, MD,PhD, Director of Clinical Quality and Analytics
Cottage Health System
Analysis of: No Quality Benefits Seen with Electronic Health Records (www.medpagetoday.com)
The porridge of attention being lavished upon anything related to augmentation of quality and outcomes in medical practice is becoming counterproductive and is obscuring important "currents" of information. To summarize EHR's as offering no benefit is akin to saying that the iphone given to John F Kennedy's...
July 11, 2007
Welcome addition
Analysis of: Shire Receives Approvable Letter from FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD (www.pipelinereview.com)
This is a helpful agent in ADHD for hyperactive symptoms. A long-acting form is critical in ADHD so no doses need to interrupt the school day. More even blood levels also an advantage.

Previous Page : 1 2 3 4 Next11 to 20 of 32

Analytics


Generated at 2009-01-07T19:00:58.307